Related Experiment Video
Updated: Aug 11, 2026
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation
Su E Low1, Janet M Horsman, Stephen J Walters
1YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
Abstract:
Using significant factors from multivariate analyses, based on 20 putative markers from a consecutive series of 1198 Sheffield Lymphoma Group patients, risk-adjusted prognostic models had been previously derived for Hodgkin's disease (HD) (using age, albumin and lymphocyte count) and non-Hodgkin's lymphoma (NHL) grade II (based on albumin, age, erythrocyte sedimentation rate, lactate dehydrogenase and stage). Data from 6728 patients on the British National Lymphoma Investigation database were used for validation: thus the models were applied to 4411 patients with HD and 2317 patients with NHL grade II. Survival curves derived from these validation groups confirmed our risk models.
